ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Comment by Chainsawwon Nov 20, 2010 2:09am

257 Views

Post# 17733641

RE: RE: BROKER SUMMARY NOV 19

Hi, the next gap i see is at the .80 range but we will probably encounter some resistance between .55 and .60 first.
But of course we could have some stellar news and bust through that resistance level with power and move up quicker. I suspect that as the price moves up the sellers will come out of the woodwork. Usually if its a sharp and quick spike it drops back sooner than if its a more gradual move upwards.
We are looking a whole lot better than a week ago and this is the beginning of the uptrend on a weekly basis. We need to hold above the .42 range for a while and it looks very good so far.
Cheers,

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide